Clinical trials
Patient Safety clinical trials
Below are recruiting patient safety clinical trials, each written for real people, not researchers. We’re tracking 1,317 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06558253RecruitingPhase 1
Coenzyme I for blood recovery after cord blood transplant
This trial tests whether a drug called Coenzyme I (given by injection) can help your blood cells recover faster after a cord blood transplant for blood cancer. It is for people who are getting this type of transplant for the first time and are in fairly good health otherwise.
Hefei, AnhuiAges 18–60 - NCT06408688RecruitingPhase 4
Mistletoe extract added to immunotherapy for advanced solid tumors
This trial tests whether adding mistletoe extract (Iscador) to standard immunotherapy can make the treatment safer and boost the immune system's response against advanced solid tumors (excluding skin cancer). If you are already receiving or about to start a checkpoint inhibitor, this study may help understand if the combination works better.
BadenAges 18 years+ - NCT06757153RecruitingEarly Phase 1
NRG-103 injection for recurrent glioblastoma patients
This trial tests an injection called NRG-103 given directly into the cavity where a recurrent brain tumor was removed. It is for people with glioblastoma that has come back and who have already had standard treatments.
Wuhan, HubeiAges 18 years+ - NCT07498725RecruitingPhase 1/Phase 2
Study of LRK-4189 for solid tumors that have spread or can't be removed
This trial tests a new drug called LRK-4189, alone or with other treatments, for people with advanced solid tumors that have worsened despite prior therapy. The goal is to see if it is safe, tolerable, and helpful against the cancer.
NiceAges 18 years+ - NCT07483827RecruitingPhase 1
Testing CPV-104 safety in healthy people and C3G patients
This trial tests a new drug called CPV-104. First, healthy volunteers will receive a single dose to check safety. Then, people with C3 glomerulopathy (a rare kidney disease) will receive multiple doses to see if it helps and is safe.
ViennaAges 18 years+ - NCT07483372RecruitingPhase 1
SC101 injection for resistant hypertension with kidney disease
This early-phase trial tests an injection called SC101 into the fat around your kidney. It aims to help lower blood pressure in people whose hypertension is poorly controlled despite multiple medications and who have moderate to severe chronic kidney disease.
Suzhou, JiangsuAges 18–65 - NCT04782232Recruiting
Study of a new blood tube for heart pump patients
This registry study checks whether a new venous blood tube used with a heart pump is safe and practical for people whose right heart is failing and who may need a heart transplant. If you qualify, your care team would monitor how the device works over time.
MunichAges Any age - NCT07388602RecruitingPhase 3
New drug combo for newly diagnosed AL amyloidosis
This trial tests a new drug (SCTC21C) combined with three standard chemotherapy medicines for people who have just been diagnosed with AL amyloidosis. The goal is to see if adding the new drug helps reduce the abnormal protein deposits better than the standard treatment alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07374679Recruiting
Long-term safety and effectiveness of stem cells for rotator cuff disease
This study follows up with people who already received an experimental stem cell treatment for rotator cuff disease in a previous trial. It aims to check if the treatment remains safe and effective over time.
Seoul, KoreaAges 19 years+ - NCT07329361Recruiting
Frozen platelet-rich plasma injections for knee osteoarthritis
This trial tests whether frozen platelet-rich plasma (PRP) injections into the knee can safely reduce pain and improve function in people with knee osteoarthritis. It's for those with mild to moderate knee arthritis who haven't had certain recent knee treatments.
Vitoria-Gasteiz, Araba/ÁlavaAges 40–85 - NCT07297212RecruitingPhase 2
Testing the drug pumitamig for recurrent glioblastoma
This trial tests an investigational drug called pumitamig (also known as BNT327) in people whose glioblastoma has come back after standard treatment with radiation and temozolomide. The goal is to see if the drug is safe and whether it can help slow or stop tumor growth.
BeijingAges 18–75 - NCT07297329RecruitingPhase 3
Newly diagnosed multiple myeloma trial for transplant-ineligible patients
This trial tests a new drug called SCTC21C combined with standard treatments (bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see if this combination is safe and works better than current options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07297602RecruitingPhase 2
Oral roflumilast for moderate to severe eczema in teens and adults
This study tests an oral medicine called roflumilast to see if it helps treat moderate to severe eczema in people aged 12 and up who haven't used other systemic treatments recently. It's a pilot study to check both safety and how well it works.
Al Mansurah, Dakahlia GovernorateAges 12 years+ - NCT07230171Recruiting
Short-term S-ketamine for fibromyalgia pain relief
This trial tests if low-dose S-ketamine, given as a short intravenous infusion, can safely improve fibromyalgia pain and other symptoms for people who haven't gotten enough relief from non-drug treatments. S-ketamine is a fast-acting medicine that blocks pain signals and may help reset how the brain processes pain.
BeijingAges 18 years+ - NCT06947707Recruiting
Blood thinners for brain blood clot in Chinese patients
This trial tests two blood thinner medicines, edoxaban and rivaroxaban, in Chinese patients with a blood clot in a brain vein (cerebral venous thrombosis). It aims to see if these medicines are safe and work well.
Beijing, Beijing MunicipalityAges 18–80 - NCT07169500RecruitingPhase 1/Phase 2
CAR-T with or without stem cell transplant for young women with myeloma
This trial tests a new immune cell therapy (BCMA-CART) alone or combined with a stem cell transplant for women aged 18-55 with multiple myeloma. It aims to see if this treatment is safe and effective.
Tianjin, Tianjin MunicipalityAges 18–50 - NCT07128797RecruitingPhase 1
Safety and tolerability of B1344 injections for NAFLD
This trial tests whether multiple injections of B1344 are safe and tolerable in people with nonalcoholic fatty liver disease (NAFLD). It aims to find the right dose and check how the drug works in the body.
Beijing, Beijing MunicipalityAges 18–75 - NCT07051629RecruitingPhase 1
Testing a new epilepsy medicine for safety in healthy people and patients
This study tests a new medicine called SIF001 for safety. It first gives the medicine to healthy volunteers, and then to people with epilepsy who have seizures even while on their current medicines. The goal is to find a safe dose.
Tucson, ArizonaAges 18–70 - NCT07010497RecruitingPhase 2
Study of a three-drug combo for advanced liver cancer
This trial tests a new combination of three drugs (Irpagratinib, Atezolizumab, and Bevacizumab) for people with advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and effective.
SeoulAges 19 years+ - NCT06981325RecruitingPhase 2
Cemiplimab for advanced basal cell carcinoma
This trial tests cemiplimab, an immunotherapy drug, as a first treatment for advanced basal cell carcinoma that cannot be removed with surgery or radiation. The goal is to see if it can shrink or control the cancer.
ErfurtAges 18 years+ - NCT06932003RecruitingPhase 1/Phase 2
Testing a new tablet for hidradenitis suppurativa
This trial is testing an experimental tablet called LT-002-158 in adults with moderate to severe hidradenitis suppurativa (HS) that hasn't improved enough with standard treatments. The goal is to see if it's safe and helps reduce painful lumps and abscesses.
Beijing, Beijing MunicipalityAges 18–75 - NCT06863376RecruitingPhase 2
Carbocisteine for fatty liver disease: safety and benefit study
This study tests a medicine called carbocisteine to see if it can help treat nonalcoholic fatty liver disease (NAFLD). If you have a fatty liver and no other liver or kidney conditions, this trial may explore whether this drug is safe and effective for you.
TantaAges 18–65 - NCT06736275RecruitingEarly Phase 1
Testing a new gene therapy for advanced solid tumors
This trial tests an experimental gene therapy called SXRN for people with advanced solid tumors that haven't responded to standard treatments. The study aims to see if it's safe and may help slow the disease.
BeijingAges 18–75 - NCT06733246Recruiting
Ceretrieve Device for acute ischemic stroke treatment
This study tests a new device called Ceretrieve that is designed to remove blood clots from large arteries in the brain for people having a severe ischemic stroke. If you are eligible, you will receive the device treatment (a mechanical thrombectomy) within 24 hours of your first symptoms.
HeidelbergAges 18 years+
Hear when a new Patient Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patient safety?
- Yes. Clin2 currently lists 1,317 recruiting patient safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patient safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patient safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.